DOCSLIB.ORG

Written Evidence UK Centre for Medical

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Written Evidence UK Centre for Medical Science & Technology Committee: Written evidence UK Centre for Medical Research & Innovation (UKCMRI) This volume contains the written evidence accepted by the Science & Technology Committee for the UK Centre for Medical Research & Innovation (UKCMRI) inquiry. UKCMRI Author UKCMRI Author 00 BIS 17 Camden Green Party 01 Faculty of Pharmaceutical Medicine 18 Councillor Roger Robinson, St Pancras and Somers Town Ward 02 The Academy of Medical Sciences 20 John Mason 03 Director, Medical Research Council 21 T Morgan National Institute for Medical Research 04 UKCMRI Limited 22 Frankie Biney 04a Supplementary 04b Further supplementary 04c Further supplementary 05 Robert Henderson 23 Rt. Hon. Frank Dobson MP 05a Supplementary 06 Medical Research Council’s National Trade Union Side 07 Mireille Burton 08 King’s College London 09 Joint submission: Cancer Research UK, MRC, UCL, and Wellcome Trust 09a Supplementary (MRC) 09b Further supplementary (MRC) 10 Isabel Vasseur 11 St Pancras and Somers Town Planning Action 11a Supplementary 12 Imperial College London 13 The Public & Commercial Services Union 14 Action for our Planet 15 GlaxoSmithKline R&D 16 Professor G G Dodson 16a Supplementary 16b Further supplementary As at 20 April 2011 Written evidence submitted by the Department for Business, Innovation & Skills (BIS) (UKCMRI 00) The UK Centre for Medical Research and Innovation (UKCMRI) will be a world-class centre for biomedical research, located in the London Borough of Camden. UKCMRI will be an independent institute funded by the Medical Research Council, Cancer Research UK, the Wellcome Trust and University College London. The funding partners, and separately UKCMRI, will also be submitting a memorandum to the Select Committee. 1. Review the progress on the UKCMRI since 2008 and assess the plans for the coming years. 1.1. Substantial progress has been made since 2008 on setting up the UK Centre for Medical Research and Innovation (UKCMRI). The Department for Business, Innovation and Skills (BIS) gave the MRC permission to sign the Joint Venture Agreement (JVA) to establish UKCMRI. This decision was taken following detailed discussions with the Medical Research Council (MRC) on the content of the documents and BIS and HM Treasury scrutiny of the JVA. In view of the revised public funding arrangements for the project (detailed below), the Department of Health also gave its consent for MRC to sign the agreement. The JVA was signed by the chief executives of the four partners and Sir David Cooksey (as Chair of the UKCMRI Steering Group) in the presence of The Rt Hon David Willetts M.P. Minister for Universities and Science, and Earl Howe on 9 November 2010. 1.2. The JVA limits the maximum commitments of the founders to UKCMRI construction costs. A commitment by MRC to fund its share of construction costs requires approval by BIS and HM Treasury Ministers of the MRC’s Final Business Case. BIS expects to receive the Final Business Case in January 2011. 1.3. The UKCMRI project has been reviewed on three occasions by the Office of Government Commerce since 2008. 1.3.1. The OGC Major Projects Review Group (MPRG) reviewed the project in May 2009; the principal issues raised during this review concerned the degree of protection of the public interest in the then project arrangements and have been addressed by the JVA. 1.3.2. A second MPRG review was carried out in March and April 2010. This highlighted issues about cost and risk management. These have now been addressed. 1.3.3. The Office for Government Commerce (OGC) undertook another review as part of its Major Projects Assessment Review across government in July 2010. This review specifically examined 2 the potential for cost savings of major projects, providing information to the Spending Review process. In summary, this review gave a delivery confidence assessment of “amber-green” to UKCMRI. The review concluded that there were no viable options for significant cost savings and did not recommend cancellation or relocation. 1.4. Government approval was given for purchase of the 3.5 acre site for UKCMRI on Brill Place, adjacent to the British Library. The sale was completed on 13 June 2008. The land was purchased from the Department for Culture, Media and Sport for £85m, of which £46.75m was provided by MRC. The JVA states that the Founders will remain as freeholders of the land and buildings, which will be leased to UKCMRI. 1.5. A Construction Project Board has been established (comprising three representatives of UKCMRI and one from each founder); this supports the Executive Team of UKCMRI in the day-to-day management of the construction. The board meets monthly. An observer from BIS attends this board. 2. What do the four partners hope to achieve from the project and what new technologies and innovations are being considered? 2.1. A detailed vision for research at UKCMRI has been set out in their Scientific Vision and Research Strategy document. This will be covered in more detail in submissions from UKCMRI and the founding partners. 2.2. Government provision of funding to MRC for UKCMRI is on the basis that: 2.2.1. It will be one of the most significant developments in UK biomedical science for a generation. 2.2.2. Its goal will be to understand the biology underlying human health, finding ways to prevent and treat the most significant diseases affecting people today. 2.2.3. By enabling interactions between physical, biomedical and clinical scientists, UKCMRI will play a key role in ensuring that advances in biomedical sciences are translated swiftly and effectively into benefits for patients in the NHS. 2.2.4. By fostering collaboration with other centres of excellence, UKCMRI will harness the full capacity of this country’s brightest and best researchers for the benefit of patients and the economy. 3. Is the financing of the UKCMRI robust and justified, with particular reference to the public support for the project and the knock-on effect on budgets for other research? 3 3.1. As part of the spending review in October 2010, £220m of funding was announced for the construction of UKCMRI, to come from the Department for Health. The spending review announcement represents the MRC’s expected share of capital spend on UKCMRI construction in the four years of the spending review period, with the remainder of the capital falling in the next spending review period being provided by BIS. 3.2. Government funding for the MRC contribution to UKCMRI remains subject to approval of the MRC Full Business Case. This Business Case will be subject to robust scrutiny and approval will be dependent on planning permission for UKCMRI being granted. BIS and HMT expect a submission of a draft of the Full Business Case from MRC in January, with a decision on the final Full Business Case in Spring 2011, subject to passing through the scrutiny process and a positive decision on planning. 3.3. In addition to the construction costs, MRC will need to fund the costs of the transition from NIMR to UKCMRI. These costs include moving equipment and any staff redundancies that result from the transition. 3.4. MRC expect to provide funding additional to the £220m from the Department of Health from their resource and capital budgets, from commercial income and from sale of the Mill Hill and National Temperance Hospital sites. 3.5. The MRC expects to provide ongoing funding for UKCMRI at the same level as it presently provides for NIMR (£42m p.a.). 4. What are the risk assessment arrangements to ensure the safety of the site? 4.1. As stated in the Government response to the 2008 House of Commons Innovation, Universities, Science and Skills Committee inquiry into Biosecurity in UK Research Laboratories, there is no reason in principle why bioscience laboratories should not be built in urban areas. It is, however, essential that whatever the location, the facilities must have robust security measures in place that are appropriate to the location. 4.2. UKCMRI will provide detail on these security measures to the select committee. 5. What are the arrangements for the closure of the existing National Institute for Medical Research at Mill Hill? 5.1. The MRC will provide information on arrangements for closure of NIMR. Department for Business, Innovation & Skills (BIS) 18 January 2011 4 Written evidence submitted by the Faculty of Pharmaceutical Medicine (UKCMRI 01) Thank you for giving the Faculty of Pharmaceutical Medicine the opportunity to submit comments on the proposed UK Centre for Medical Research and Innovation (UKCMRI). Whilst we do not have any specific comments to make on your questions, we would like it to be noted that we wholeheartedly support the establishment of the UKCMRI. We welcome the Government’s support of scientific and medical research in this challenging economic climate, and its commitment to maintaining and improving the UK’s position as a global leader in medical research. Faculty of Pharmaceutical Medicine 2 December 2010 5 Written evidence submitted by The Academy of Medical Sciences (UKCMRI 02) I am writing as President of the Academy of Medical Sciences to respond to the House of Commons Science and Technology Committee inquiry into the UK Centre for Medical Research and Innovation (UKCMRI). The Academy welcomes the Government’s continued commitment to UKCMRI, alongside investment by other funders. UKCRMI aims to translate increasingly specialised scientific research into clinical applications that will benefit UK patients, and fully deserves strong and enduring Government support. By capitalising on the unprecedented recent discoveries and technological advances in the medical sciences, UKCMRI will play a vital role in rebuilding the UK economy and improving health. UKCMRI represents a groundbreaking partnership between the Medical Research Council (MRC), Cancer Research UK, the Wellcome Trust and University College London, which showcases how public investment can be magnified through collaborations with other sectors.
Load more

Recommended publications
  • [email protected] FST Journal Publishes Summaries of All the Talks Given at Its Meetings
    journal The Journal of The Foundation for Science and Technology fstVolume 22 Number 2 March 2018 www.foundation.org.uk Editorial Sir David Cannadine: The role of the Academies in providing independent advice to Government An industrial strategy for the UK Lord Hennessy: Searching for a strategy that makes a difference Lord Heseltine: Establishing a strategy for the whole economy Lord Willetts: A tension at the heart of Government activity A business strategy for Scotland Professor Iain Gray: Translating research excellence into economic benefit Nora Senior: Plugging gaps in performance Dame Susan Rice: An ecosystem for business Paul Wheelhouse: Driving innovation Meeting air quality targets Dr Stephen Bryce: The energy emissions challenge Professor Frank Kelly: The health consequences of air pollution Diagnosing cancer earlier Sir Harpal Kumar: Early diagnosis has the potential to transform patient outcomes Dr Clare Turnbull: Using genetics to combat cancer The rise of machine learning Dr Mike Lynch: An opportunity or a threat to society? Dr Claire Craig: Giving society the confidence to embrace opportunities Amir Saffari: The potential to augment human efforts Dame Wendy Hall: The opportunities for the UK Comment Norman Lamb: The future of social care Obituary The Rt Hon Sir Brian Neill COUNCIL AND TRUSTEES COUNCIL CHIEF EXECUTIVE Chair Dr Dougal Goodman OBE FREng The Earl of Selborne* GBE FRS Deputy Chairs The Baroness O’Neill of Bengarve* CH CBE FBA FRS FMedSci Dr Mike Lynch* OBE FRS FREng DL President, The Royal Society Professor
    [Show full text]
  • Trustees' Annual Report and Financial Statements 31 March 2016
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES TRUSTEES’ ANNUAL REPORT AND FINANCIAL STATEMENTS 31 MARCH 2016 Charity registration number: 1140062 Company registration number: 6885462 The Francis Crick Institute Accounts 2016 CONTENTS INSIDE THIS REPORT Trustees’ report (incorporating the Strategic report and Directors’ report) 1 Independent auditor’s report 12 Consolidated statement of financial activities 13 Balance sheets 14 Cash flow statements 15 Notes to the financial statements 16 1 TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2016, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the Institute’ or ‘the Crick) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick
    [Show full text]
  • UKRI Explainer
    UK Research and Innovation (UKRI) What is UKRI? UK Research and Innovation (UKRI) was established by the UKRI delivers the majority of public funding for research Higher Education and Research Act 2017 and was launched and innovation in the UK. It will play a central role in in April 2018. The purpose of UKRI is to create a strong, realising the UK Government’s ambition of 2.4% of gross agile and joined up funder of research and innovation for domestic product (GDP) investment in research and the UK. UKRI brings together the seven Research Councils, development (R&D) by 2027. This explainer summarises Innovate UK and Research England (formally the Higher UKRI’s structure, governance and operation to support Education Funding Council for England (HEFCE)). UKRI and discussion over how this funding is distributed. its constituent Councils published their first Delivery Plans in June 20191. FIGURE 1 Who makes up UKRI? UK Research and Innovation (UKRI) Engineering UKRI is made up of nine Councils: seven Research Councils, Innovate UK Economic and Physical and Social and Research England. Sciences Research Research Council Research Councils Council (ESRC) (EPSRC) The seven Research Councils, divided by scientific discipline, support Biotechnology and Biological Medical excellent research by providing grant funding, access to excellent research Sciences Research facilities and investing in infrastructure and institutions. Research Council Council (MRC) Innovate UK (BBSRC) The UK’s innovation agency, works with companies to de-risk, enable and support innovation, including through providing innovation grants and UK Research and Science and Arts and investing in Catapult centres. Technology Innovation (UKRI) Humanities Facilities Research Research England Council Council Research England supports English Higher Education providers to (STFC) (AHRC) deliver funding for research and knowledge exchange formerly performed by HEFCE.
    [Show full text]
  • Ukcrc Agenda
    MINUTES UK CLINICAL RESEARCH COLLABORATION BOARD MEETING 11 October 2012 Minutes of the meeting held on 11 October 2012, Room 1, 13th Floor, MRC, One Kemble Street, London WC2B 4TS Present Members Professor Dame Sally Davies – Department of Health, England (Chair, DH) Sir John Savill – Medical Research Council (Deputy Chair/MRC) Bina Rawal – The Association of the British Pharmaceutical Industry (ABPI) Dr Helen Bodmer – Department for Business, Innovation and Skills (BIS) Sarah Buckland – INVOLVE Sharmila Nebhrajani - Association of Medical Research Charities (AMRC) Dr Russell Hamilton – Department of Health, England (DH) Harpal Kumar – Cancer Research UK (CRUK) Dr Richard Tiner – Academy of Medical Royal Colleges (AOMRC) Beth Thompson – Wellcome Trust Mike Stevens – Scottish Government Health Directorates Professor Bernie Hannigan – Health & Social Care R&D, Northern Ireland Steve Bates – BioIndustry Association (BIA) Michael Bowdery – National Institute for Social Care and Health Research, Welsh Assembly Government (NISCHR) John Hughes - Patient/Public Member Andrew Russell – Patient/Public Member Sir Ron Kerr – NHS Confederation Sir Nick Partridge – Patient/Public Member (Deputy Chair) David Adams – Academy of Medical Sciences (AMS) Professor Carole Longson – National Clinical Institute for Health and Clinical Excellence (NICE) Andy French - Medicines and Healthcare products Regulatory Agency (MHRA) Caroline Shaw - The Association of University Hospitals UK Paul Hubbard – Higher Education Funding Councils (HEFC) Professor Iain Cameron
    [Show full text]
  • Cancer Research Uk and Hsbc Join Forces in Usd25m Partnership to Build the Francis Crick Institute and Support the Scientific Le
    Thursday 22 October CANCER RESEARCH UK AND HSBC JOIN FORCES IN US$25M PARTNERSHIP TO BUILD THE FRANCIS CRICK INSTITUTE AND SUPPORT THE SCIENTIFIC LEADERS OF THE FUTURE Cancer Research UK today announced a partnership with HSBC to support the scientific leaders of tomorrow through a contribution of US$25 million towards the development of the Francis Crick Institute. The new state‐of‐the‐art biomedical research facility is currently being built in King’s Cross, in the heart of London. HSBC’s support is contributing to the cost of the construction of the Francis Crick Institute which is due to open in 2016. Cancer Research UK will receive US$5m per year from HSBC for the next five years (2015‐2019). The Francis Crick Institute will see more than 1,200 scientists, representing a variety of disciplines, collaborating to tackle the diseases that pose the greatest threat to humanity – cancer, heart disease, lung disease, infectious diseases such as HIV and malaria and many more. The collaboration between HSBC, Cancer Research UK and the Francis Crick Institute will be marked by 150 PhD students who will be provided with an opportunity to conduct vital research at the new institute. The young scientists will be selected from across the world for the PhD programme. Harpal Kumar, Chief Executive Officer at Cancer Research UK, said: “Cancer Research UK has a long history of working with HSBC, but this donation really is game‐changing for us. This extraordinarily generous gift will cement our commitment to investing in the highest quality science by helping us to support some of the best and most imaginative scientists in the world.” HSBC’s donation is part of a series of community investments being made globally to mark HSBC’s 150th anniversary.
    [Show full text]
  • Paterson Institute for Cancer Research Scientific Report 2009 Cover Images
    Paterson Institute for Cancer Research Scientific Report 2009 Cover images Top Mitotic BPAE cells in anaphase. F-actin is labelled with Texas Red-x phalloidin. Microtubules, in green, are la - belled with mouse anti- α-tubulin BODIPY FL goat anti- mouse IgG. Blue nuclear staining with DAPI. Imaged on the Spinning Disk Confocal microscope. Image provided by Achille Dunn, Advanced Imaging Fa - cility. Bottom Immunostaining demonstrating blood vessels surrounding a tumour. Glut1 immunostaining (red) specifically labels veinous structures whereas arterial structures are Glut1 negative. Red blood cells in the vessels were detected by inherent autofluorescence (green) and cell nuclei were labelled with DAPI (blue). Image provided by Darren Roberts, Clinical and Exper - imental Pharmacology Group. Scientific Report 2009 Paterson Institute for Cancer Research Contents Director’s Introduction 5 Georges Lacaud 38 Stem Cell Biology Group Research Highlights 8 Valerie Kouskoff 40 Stem Cell and Haematopoiesis Group Drug Discovery in the Manchester 12 Cancer Research Centre Akira Orimo 42 Stromal-Tumour Interaction Group Research Groups – Paterson Institute Research Groups – The University of Manchester School of Cancer and Enabling Sciences Crispin Miller 16 Applied Computational Biology and Bioinformatics Group Robert E Hawkins and Peter L Stern 46 Biological, Immune and Gene Therapy Group Geoff Margison 18 Carcinogenesis Group Vaskar Saha 48 Children’s Cancer Group Karim Labib 20 Cell Cycle Group Tim Illidge 50 Targeted Therapy Group Iain Hagan 22
    [Show full text]
  • The Francis Crick Institute Limited
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES ANNUAL REPORT AND FINANCIAL STATEMENTS 31 March 2019 Charity registration number: 1140062 Company registration number: 6885462 1 The Francis Crick Institute Limited annual report and financial statements 2019 Contents Chairman’s letter 3 Director’s introduction 4 Trustees’ report (incorporating the strategic report and 5 directors’ report) Independent auditor’s report 33 Consolidated statement of financial activities (incorporating 37 the income and expenditure account) Balance sheets 38 Consolidated cash flow statement 39 Notes to the financial statements 40 2 The Francis Crick Institute Limited annual report and financial statements 2019 Chairman’s letter As Chairman of the Crick, I am delighted with the progress the Institute has made across all of its strategic objectives in the last twelve months. Earlier this year, we met with the Crick’s core funders after their Establishment Review had assessed the progress made on setting up the Institute. The resulting strong endorsement is a testament to what has been achieved with regard to set-up, governance structures and strategic direction. This progress is borne out by recent successes which give me great confidence that the Crick is already beginning to deliver on its charitable mission to understand the fundamental biology that underlies health and disease. Over 400 papers were published by Crick researchers in the last year and it is a testament to the reputation of the Crick for high quality biomedical research that it continues be a magnet for talented Group Leaders and other staff. We are receiving around 100 applications for each Group Leader position, and over the last 12 months, had more than 30 applications for every postdoctoral fellowship and over 1700 graduate student applications for 49 PhD positions.
    [Show full text]
  • Annual Report and Financial Statements
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES ANNUAL REPORT AND FINANCIAL STATEMENTS 31 March 2017 Charity registration number: 1140062 Company registration number: 6885462 WHO WE ARE CONTENTS The Francis Crick Institute is a Trustees’ report (incorporating the strategic report and biomedical discovery institute dedicated directors’ report) 1 to understanding the fundamental Independent auditor’s report 10 biology underlying health and illness. Consolidated statement Our work is helping to understand why of financial activities 11 disease develops and to translate this Balance sheets 12 into new ways to prevent, diagnose and Cash flow statements 13 treat illnesses such as cancer, heart disease, strokes, infections, and Notes to the financialstatements 14 neurodegenerative diseases. For more information www.crick.ac.uk TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2017, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the institute’ or ‘the Crick’) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick Institute.
    [Show full text]
  • UK Research and Innovation (UKRI)
    UK Research and Innovation (UKRI) What is UKRI? UK Research and Innovation (UKRI) was established by the UKRI delivers the majority of public funding for research Higher Education and Research Act 2017 and was launched and innovation in the UK. It will play a central role in in April 2018. The purpose of UKRI is to create a strong, realising the UK Government’s ambition of 2.4% of gross agile and joined up funder of research and innovation for domestic product (GDP) investment in research and the UK. UKRI brings together the seven Research Councils, development (R&D) by 2027. This explainer summarises Innovate UK and Research England (formally the Higher UKRI’s structure, governance and operation to support Education Funding Council for England (HEFCE)). UKRI and discussion over how this funding is distributed. its constituent Councils published their first Delivery Plans in June 20191. FIGURE 1 Who makes up UKRI? UK Research and Innovation (UKRI) Engineering UKRI is made up of nine Councils: seven Research Councils, Innovate UK Economic and Physical and Social and Research England. Sciences Research Research Council Research Councils Council (ESRC) (EPSRC) The seven Research Councils, divided by scientific discipline, support Biotechnology and Biological Medical excellent research by providing grant funding, access to excellent research Sciences Research facilities and investing in infrastructure and institutions. Research Council Council (MRC) Innovate UK (BBSRC) The UK’s innovation agency, works with companies to de-risk, enable and support innovation, including through providing innovation grants and UK Research and Science and Arts and investing in Catapult centres. Technology Innovation (UKRI) Humanities Facilities Research Research England Council Council Research England supports English Higher Education providers to (STFC) (AHRC) deliver funding for research and knowledge exchange formerly performed by HEFCE.
    [Show full text]
  • Sir, Some of the Most Important Medical Discoveries of Our Time
    Sir, Some of the most important medical discoveries of our time, such as establishing the link between smoking and cancer, would not have been possible without the use of personal data. These discoveries have saved countless lives and continue to grow our understanding of how to treat and prevent disease. There is a very real risk that the EU Data Protection Regulation currently being negotiated in Brussels will make crucial research unworkable. Disproportionate limits on the use of personal data in health research have been proposed that would immediately threaten studies across Europe involving millions of participants. It’s critical that these restrictions are not included in the final version of the law. Protecting people’s privacy is vital. Strong safeguards and governance structures already exist to help ensure that personal information is used safely, ethically and securely in research. The proposed regulation must work with this system, rather than creating additional bureaucracy that will compromise important research. We urge the European institutions to work together to ensure that the Regulation strikes an appropriate balance that protects the interests of individuals while enabling research that benefits us all. Harpal Kumar Chief Executive. Cancer Research UK Rector Anders Overgaard Bjarklev Chairman of the Danish Rectors’ Conference - Universities Denmark Prof Peter Strohschneider President of the German Research Foundation (DFG) Professor Martin McKee President, European Public Health Association (EUPHA) Professor Françoise
    [Show full text]
  • The Francis Crick Institute
    7/13/2017 Knighthood for Dr Richard Treisman | The Francis Crick Institute TheT hFrancisis site uses c oCrickokies to improve yoHOMEur expeABOUTrience. USBy coRESEARCHntinuing to usOURe thi sBUILDING site, you areSTRATEGY agreeing to tWHAT'Sheir use .ON MoreNEWS about CCONTACTookies C USontinue Institute Home / News / News archive / 2016 / 06 / 11 / Knighthood for Dr Richard Treisman Knighthood for Dr Richard Treisman 11 June 2016 Dr Richard Treisman, Research Director at the Francis Crick Institute, has been knighted in the Queen's Birthday Honours for services to biomedical science and to cancer research. News archive Richard became Director of 2017 Laboratory Research at the Imperial Cancer Research Fund 2016 in 1999, and Director of the Cancer Research UK London 2015 Research Institute upon the foundation of CRUK in 2002. 2014 Dr Richard Treisman, biochemist, molecular biologist and 2013 Research Director at the Francis Crick Institute, has been knighted in the Queen's Birthday Honours for services to 2012 biomedical science and to cancer research. LINKS 2011 Internal 2010 Richard's research seeks to understand at the molecular level how chemical signals arriving at a cell's surface are transmitted to the Richard Treisman research laboratory 2009 cell nucleus to alter the expression of specific genes. 2008 External His main focus is on a system known as the SRF network, which Science news Cancer Research UK regulates expression both of genes important for cell CrickNews proliferation, and for cell movement and adhesion, functions critical for cancer cell growth and spread. Press releases Publications Richard Treisman received his PhD in 1981, for work on virus gene expression with Bob Kamen at the former Imperial Cancer Sitemap Research fund.
    [Show full text]
  • Francis Crick Institute Annual Review 2015/2016
    FRANCIS CRICK INSTITUTE DISCOVERY WITHOUT BOUNDARIES ANNUAL REVIEW 2015/2016 INSIDE THIS REPORT Introduction 2 Progress against our strategy 6 Highlights from the year 10 Our building: The Crick Laboratory 20 Science highlights 24 Facts and figures 36 1 BRINGING IT ALL TOGETHER OUR FIRST YEAR The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the fundamental biology underlying health and illness. Our work is helping to understand why disease develops and to translate this into new ways to prevent, diagnose and treat illnesses such as cancer, heart disease, strokes, infections, and neurodegenerative diseases. The Francis Crick Institute Progress against our strategy 2 Annual review 2016 Highlights from the year Our building: The Crick Laboratory Science highlights Facts and figures INTRODUCTION WITH PAUL NURSE By bringing together scientists from many disciplines, the Crick will help to improve people’s lives and keep the UK at the forefront of biomedical research. 3 Welcome to the first annual review The second task has been establishing and embedding a new institute from the merger of our parent of the Francis Crick Institute, a institutes, the MRC’s National Institute of Medical discovery institute dedicated to Research (NIMR) and Cancer Research UK’s London Research Institute (LRI). On 1 April 2015, this merger understanding the fundamental brought together nearly 1,200 staff. The practicalities biology underpinning human of establishing a new, single institute have been numerous – from brand new online systems for finance, health. Our work is furthering procurement, and HR to new logistical arrangements knowledge about why disease such as a unified delivery service.
    [Show full text]